These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1305 related articles for article (PubMed ID: 23970365)

  • 1. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy.
    Huang WY; Kao CH; Huang WS; Chen CM; Chang LP; Lee MS; Chao HL; Chiu CH; Lo CH; Jen YM
    J Nucl Med; 2013 Oct; 54(10):1710-6. PubMed ID: 23970365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
    Bollineni VR; Widder J; Pruim J; Langendijk JA; Wiegman EM
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e551-5. PubMed ID: 22417800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiation of tumor recurrence from radiation-induced pulmonary fibrosis after stereotactic ablative radiotherapy for lung cancer: characterization of 18F-FDG PET/CT findings.
    Nakajima N; Sugawara Y; Kataoka M; Hamamoto Y; Ochi T; Sakai S; Takahashi T; Kajihara M; Teramoto N; Yamashita M; Mochizuki T
    Ann Nucl Med; 2013 Apr; 27(3):261-70. PubMed ID: 23299492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma.
    Lee JW; Paeng JC; Kang KW; Kwon HW; Suh KS; Chung JK; Lee MC; Lee DS
    J Nucl Med; 2009 May; 50(5):682-7. PubMed ID: 19372474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of ¹⁸F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma.
    Song MJ; Bae SH; Yoo IeR; Park CH; Jang JW; Chun HJ; Choi BG; Lee HG; Choi JY; Yoon SK
    World J Gastroenterol; 2012 Jul; 18(25):3215-22. PubMed ID: 22783045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorodeoxyglucose positron emission tomography response and normal tissue regeneration after stereotactic body radiotherapy to liver metastases.
    Stinauer MA; Diot Q; Westerly DC; Schefter TE; Kavanagh BD
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e613-8. PubMed ID: 22494588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer.
    Haug AR; Tiega Donfack BP; Trumm C; Zech CJ; Michl M; Laubender RP; Uebleis C; Bartenstein P; Heinemann V; Hacker M
    J Nucl Med; 2012 Mar; 53(3):371-7. PubMed ID: 22331219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of (18)F-FDG PET to predict tumor progression and survival in patients with intermediate hepatocellular carcinoma treated by transarterial chemoembolization.
    Kim MJ; Kim YS; Cho YH; Jang HY; Song JY; Lee SH; Jeong SW; Kim SG; Jang JY; Kim HS; Kim BS; Lee WH; Park JM; Lee JM; Lee MH; Choi DL
    Korean J Intern Med; 2015 May; 30(3):308-15. PubMed ID: 25995661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of ¹⁸F-FDG PET CT as an independent prognostic indicator in patients with hepatocellular carcinoma.
    Pant V; Sen IB; Soin AS
    Nucl Med Commun; 2013 Aug; 34(8):749-57. PubMed ID: 23689586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The predictive value of metabolic tumor volume on FDG PET/CT for transarterial chemoembolization and transarterial chemotherapy infusion in hepatocellular carcinoma patients without extrahepatic metastasis.
    Lee JW; Yun M; Cho A; Han KH; Kim DY; Lee SM; Lee JD
    Ann Nucl Med; 2015 Jun; 29(5):400-8. PubMed ID: 25652647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictability of preoperative 18F-FDG PET for histopathological differentiation and early recurrence of primary malignant intrahepatic tumors.
    Song JY; Lee YN; Kim YS; Kim SG; Jin SJ; Park JM; Choi GS; Chung JC; Lee MH; Cho YH; Choi MH; Kim DC; Choi HJ; Moon JH; Lee SH; Jeong SW; Jang JY; Kim HS; Kim BS
    Nucl Med Commun; 2015 Apr; 36(4):319-27. PubMed ID: 25564069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for predicting the occult nodal metastasis in T1-2N0M0 NSCLC patients staged by PET/CT: potential value in the clinic.
    Li L; Ren S; Zhang Y; Guan Y; Zhao J; Liu J; Wang Q; Chen G; Chen H; Xiang J; Fu X
    Lung Cancer; 2013 Aug; 81(2):213-7. PubMed ID: 23664030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.
    Ryu IS; Kim JS; Roh JL; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    J Nucl Med; 2013 Jul; 54(7):1032-8. PubMed ID: 23670902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive Value of 18F-FDG PET/CT for Vascular Invasion in Patients With Hepatocellular Carcinoma Before Liver Transplantation.
    Lin CY; Liao CW; Chu LY; Yen KY; Jeng LB; Hsu CN; Lin CL; Kao CH
    Clin Nucl Med; 2017 Apr; 42(4):e183-e187. PubMed ID: 28114226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Midtreatment ¹⁸F-FDG PET/CT Scan for Early Response Assessment of SMILE Therapy in Natural Killer/T-Cell Lymphoma: A Prospective Study from a Single Center.
    Khong PL; Huang B; Lee EY; Chan WK; Kwong YL
    J Nucl Med; 2014 Jun; 55(6):911-6. PubMed ID: 24819420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT.
    Heusch P; Buchbender C; Köhler J; Nensa F; Gauler T; Gomez B; Reis H; Stamatis G; Kühl H; Hartung V; Heusner TA
    J Nucl Med; 2014 Mar; 55(3):373-8. PubMed ID: 24504054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [(18)F]FDG-PET/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy.
    Herrera FG; Breuneval T; Prior JO; Bourhis J; Ozsahin M
    Radiat Oncol; 2016 Mar; 11():43. PubMed ID: 26984385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of parameters from pretreatment (18)F-FDG PET in hepatocellular carcinoma: a meta-analysis.
    Sun DW; An L; Wei F; Mu L; Shi XJ; Wang CL; Zhao ZW; Li TF; Lv GY
    Abdom Radiol (NY); 2016 Jan; 41(1):33-41. PubMed ID: 26830609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer.
    Jadvar H; Desai B; Ji L; Conti PS; Dorff TB; Groshen SG; Pinski JK; Quinn DI
    J Nucl Med; 2013 Aug; 54(8):1195-201. PubMed ID: 23785174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 66.